Table 1.
Comparison of clinical data between the two groups, n %
|
Clinical information
|
S-1 group (n = 47)
|
Gemcitabine group (n = 47)
|
χ
2
/t
|
P
value
|
| Gender | 0.092 | 0.761 | ||
| Male | 27 (57.45) | 26 (55.32) | ||
| Female | 20 (42.55) | 21 (44.68) | ||
| Types | 0.361 | 0.548 | ||
| Squamous carcinoma | 23 (48.94) | 25 (53.19) | ||
| Adenocarcinoma | 24 (51.06) | 22 (46.81) | ||
| TNM staging | 0.130 | 0.719 | ||
| Phase IIIB | 36 (76.60) | 37 (78.72) | ||
| Phase IV | 11 (23.40) | 10 (21.28) | ||
| Age (yr) | 56.95 (4.15) | 56.17 (4.01) | 0.927 | 0.357 |
| Weight (kg) | 53.94 (3.52) | 54.09 (3.61) | 0.204 | 0.839 |
| BMI (kg/m2) | 21.14 (3.21) | 21.51 (3.45) | 0.538 | 0.592 |
TNM: Tumor-node-metastasis; BMI: Body mass index.